Suchergebnisse - "Briest, Franziska"

PubPharm (18)

1

Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells

enthalten in: Frontiers in pharmacology | 2024

von von Hessert-Vaudoncourt, C. | Lelek, S. | Geisler, C. | +14

2

Genetic Characterization of Primary Mediastinal B-Cell Lymphoma : Pathogenesis and Patient Outcomes

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Noerenberg, D. | Briest, F. | Hennch, C. | +30

3

Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma

enthalten in: Leukemia | 2023

von Briest, F. | Noerenberg, D. | Hennch, C. | +27

4

Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9

enthalten in: Leukemia | 2022

von Christen, F. | Hablesreiter, R. | Hoyer, K. | +8

5

Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? - A preclinical assessment in vitro and in vivo

enthalten in: Neoplasia (New York, N.Y.) | 2021

von Briest, F. | Koziolek, E. | Albrecht, J. | +13

6

Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment

enthalten in: Cancers | 2020

von Busse, A. | Mochmann, L. | Spenke, C. | +12

7

Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms

enthalten in: Anticancer research | 2018

von Briest, F. | Wang, Y. | Arsenic, R. | +9

8

Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors

enthalten in: Neuroendocrinology | 2018

von Briest, F. | Grass, I. | Sedding, D. | +17

9

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer

enthalten in: Oncotarget | 2017

von Taromi, S. | Lewens, F. | Arsenic, R. | +18

10

Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease

enthalten in: Neuroendocrinology | 2017

von Freitag, H. | Christen, F. | Lewens, F. | +5